M&T Bank Corp boosted its stake in MEDNAX Inc (NYSE:MD) by 26.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,138 shares of the company’s stock after purchasing an additional 1,710 shares during the period. M&T Bank Corp’s holdings in MEDNAX were worth $435,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the business. Fuller & Thaler Asset Management Inc. purchased a new position in shares of MEDNAX during the third quarter valued at approximately $103,000. Delta Capital Management LLC purchased a new position in shares of MEDNAX during the fourth quarter valued at approximately $227,000. Denali Advisors LLC purchased a new position in shares of MEDNAX during the third quarter valued at approximately $185,000. YHB Investment Advisors Inc. purchased a new position in shares of MEDNAX during the fourth quarter valued at approximately $235,000. Finally, Shelton Capital Management purchased a new position in shares of MEDNAX during the fourth quarter valued at approximately $245,000. 95.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of MEDNAX Inc (MD) opened at $57.51 on Friday. The firm has a market capitalization of $5,404.50, a price-to-earnings ratio of 18.35, a P/E/G ratio of 1.43 and a beta of 0.31. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.60.
MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.04. The company had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 earnings per share. analysts predict that MEDNAX Inc will post 4.03 EPS for the current year.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.40% of the stock is owned by corporate insiders.
MD has been the topic of several research analyst reports. Piper Jaffray Companies initiated coverage on MEDNAX in a research note on Wednesday, December 13th. They set an “overweight” rating and a $58.00 target price on the stock. BMO Capital Markets boosted their target price on MEDNAX from $46.00 to $58.00 and gave the company a “market perform” rating in a research note on Monday, February 12th. SunTrust Banks set a $55.00 price target on MEDNAX and gave the stock a “hold” rating in a research note on Thursday, December 21st. Mizuho reaffirmed a “neutral” rating and issued a $53.00 price target (up from $49.00) on shares of MEDNAX in a research note on Friday, February 9th. Finally, KeyCorp set a $51.00 price target on MEDNAX and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company’s stock. MEDNAX has a consensus rating of “Hold” and a consensus target price of $54.92.
WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/23/mt-bank-corp-has-435000-holdings-in-mednax-inc-md.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.